March 20, 2019 7:52am

Sage Therapeutics (SAGE) gets FDA approval for Zulresso, a postpartum depression drug

Which renews hope that the reward outweighs the risk and time to fruition, exit or least desired - failure

However, there is news of concern for gene editing companies: World Health Organization advisers have called for a registry of studies on human genome editing. The registry would include studies that edit the DNA of eggs, sperm, and early embryos, called germline editing, and those that edit adult cells for the purpose of curing disease, which is much less controversial and is the focus of all genome-editing companies <STAT>.

Pre-open indication: 2 BUY, 1 SELLs and 3 TRADEs


Unique insights from what's likely to remain a volatile climate; RMi outlines preludes and aftermaths defining the daily dose of factors, investment thesis and objectivity!

It’s not hard to be right so often, it’s about defining expectation, refining insight and NOT being indentured to ANY financial institution! That’s why my blend of two styles “quantamental” has become common parlance among investors and traders.


Dow futures are DOWN -0.03% (-7 points), S&P futures are DOWN -0.06% (-2 points) and NASDAQ futures are DOWN -0.03% (-2 points)


US stock futures are wallowing as markets await Fed rate decision

  • The U.S. central bank is widely expected to keep rates steady later in the session, with investors monitoring a decision on the Fed’s rate projections for the next few years.

European markets were lower with the pan-European Stoxx 600 was down around 0.4% during mid-morning trade, with most sectors and major bourses in negative territory.

Asian markets slipped following a series of conflicting reports on U.S.-China trade that surfaced overnight.

Data docket: None


Wednesday’s indications in the pre-market:

The iShares Nasdaq Biotechnology (IBB) is indicating a NEGATIVE -0.06% DOWNSIDE;

The SPDR S&P Biotech ETF (XBI) is indicating is indicating a NEGATIVE -0.35% DOWNSIDE;

The Health Care Select Sector SPDR ETF (XLV) is indicating a POSITIVE +0.79% UPSIDE;

The iShares Russell 2000 (IWM) is indicating a NEGATIVE -0.15% DOWNSIDE;



Market focus is largely attuned to global trade developments, amid media reports of U.S. concerns that China is pushing back against American demands in trade talks.


After Tuesday’s “drubbing” and a FDA approval; I expect the sector to “feel some oats” and move to the upside!


From Tuesday’s closing bell post, “the sector decelerates as the IBB (-0.06%) drifts. Right again as the sector slips as I had stated, Momentum is getting edgy, resistance is wobbly and sector breadth is weakening. The upside was lean (most under a buck) awhile the downside (just under $2.00) got “checked” into the boards. Volume was also wishy-washy: 8 out of the 19 upside had higher (than the 3 month average) volume and 5 out of the 22 downside experienced greater volume (than the 3 month average).”

  • Range of the 19 upside was +0.10% (RARE) to +25.42% (HSGX +$0.03) while the 22 downside ranged from -0.04% (BLUE) to -4.01% (MDXG).
  • In March’s 13 sessions, there were 4 negative and 9 positive closes;


Companies in my headlights – It’s your decision; I provide an idea and context:

Sage Therapeutics (SAGE) closed down -$0.78 to $156.10 and was up +$7.91 or +5.07% to $164.01 - - BUY;

The title says why there should be concern for share pricing:

CRISPRS Therapeutics (CRSP) closed down again -$0.64 to $37.24 after Monday’s -$0.76 with a negative -$0. 32 or -0.86% aftermarket indication– TRADE;

Editas Medicine (EDIT) closing up +$0.14 to $24.11 after Monday’s -$0.32 with a negative -$0.01 or -0.04% aftermarket indication yet, another trading vehicle – TRADE;

Intellia Therapeutics (NTLA) closing up +$0.15 to $16.86 after Monday’s +$0.02 to $16.71 with no aftermarket indication yet, it’s STILL stuck as a trading vehicle – TRADE;

Mesoblast (MESO) closed up +$0.05 to $%5.22 after Monday’s +$0.79 with solid volume of 339.9 K shares (3 month average =45.6 K shares> and with a premium of a seesawing seven (7) sessions since 3/11‘s $4.22. Also MESO started March at $4.33, February at $4.44 and January at $4.49 with a BIG debt package. There is a negative -$0.17 or -3.26% aftermarket indications – Maintaining SELL;

ReNeuron (RENE.L) closed down -$1.00 to $75.00 after Monday’s + +$6.00 on news of its P1/2 trial – and is seeing a +$0.10 or +0.13% incline in our markets – SELL to BUY;



Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.